Rice Hall James & Associates’s Trinity Biotech TRIB Stock Holding History

Rice Hall James & Associates’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-26,344	Closed	-$2.38M	–	311
2015 Q2	$2.38M	Sell	26,344 -255	-1%	-$22.1K	0.14%	167
2015 Q1	$2.56M	Buy	26,599 +2,316	+10%	+$214K	0.15%	155
2014 Q4	$2.13M	Sell	24,283 -75	-0.3%	-$6.46K	0.13%	196
2014 Q3	$2.23M	Sell	24,358 -373	-2%	-$40.4K	0.16%	176
2014 Q2	$2.85M	Sell	24,731 -233	-0.9%	-$27.6K	0.19%	141
2014 Q1	$3.02M	Buy	24,964 +14,990	+150%	+$1.97M	0.22%	123
2013 Q4	$1.25M	Buy	+9,974	New	+$1.2M	0.09%	210

Other funds holding TRIB

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

AAM

ACK Asset Management Greenwich, Connecticut $801M AUM 60.42% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Rice Hall James & Associates's TRIB Position: Q3 2015 in Review

Rice Hall James & Associates sold out of Trinity Biotech (TRIB) in Q3 2015, closing a stake of 26,344 shares — an estimated $2.38M sold.

Rice Hall James & Associates first reported a position in TRIB in Q4 2013 and held it in 7 quarters. The position peaked at $3.02M in Q1 2014. 92 funds tracked by Wall St. Rank hold TRIB as of Q3 2015.

Rice Hall James & Associates reported no remaining Trinity Biotech position as of Q3 2015 after selling out during the quarter.
Rice Hall James & Associates sold 26,344 Trinity Biotech shares in Q3 2015, an estimated $2.38M.
Rice Hall James & Associates first reported a position in Trinity Biotech in Q4 2013 and held it in 7 quarters.
Rice Hall James & Associates's Trinity Biotech position peaked at $3.02M in Q1 2014.
92 funds tracked by Wall St. Rank held Trinity Biotech as of Q3 2015.

Based on Rice Hall James & Associates's 13F filing for Q3 2015, filed 30 Oct 2015.